Get the Stockscreener App
22.38
0.95%
0.23
Summit Therapeutics Inc stock is traded at $22.38, with a volume of 2.10M.
It is up +0.95% in the last 24 hours and down -13.93% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$22.15
Open:
$22.28
24h Volume:
2.10M
Relative Volume:
0.59
Market Cap:
$16.65B
Revenue:
$220.00K
Net Income/Loss:
$-746.08M
P/E Ratio:
-22.22
EPS:
-1.0074
Net Cash Flow:
$-211.81M
1W Performance:
+8.23%
1M Performance:
-13.93%
6M Performance:
+29.10%
1Y Performance:
+18.18%
1-Day Range:
$21.29
$22.63
1-Week Range:
$20.29
$22.63
52-Week Range:
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
305-203-2034
Address
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
22.41 | 16.45B | 220.00K | -746.08M | -211.81M | -1.0074 |
|
VRTX
Vertex Pharmaceuticals Inc
|
411.83 | 103.30B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
583.31 | 62.05B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.61 | 59.25B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
796.22 | 48.22B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
342.48 | 37.84B | 4.56B | -176.77M | 225.30M | -1.7177 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Barclays | Underweight |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Neutral |
| Jul-01-25 | Initiated | UBS | Buy |
| Jun-11-25 | Initiated | Leerink Partners | Underperform |
| Mar-26-25 | Upgrade | Citigroup | Neutral → Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-12-25 | Initiated | Evercore ISI | Outperform |
| Feb-28-25 | Initiated | Goldman | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-24 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| May-07-24 | Initiated | Citigroup | Buy |
| Mar-26-24 | Initiated | Stifel | Buy |
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
How to use Fibonacci retracement on Summit Therapeutics Inc.Gap Up & Community Verified Trade Signals - newser.com
1 Monster Stock in the Making to Buy and Hold - Yahoo Finance
Published on: 2025-10-05 07:31:28 - newser.com
How to monitor Summit Therapeutics Inc. with trend dashboards2025 Market Sentiment & Community Driven Trade Alerts - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - PR Newswire
How the European Spotlight on Ivonescimab’s Phase III Data Could Shape Summit Therapeutics (SMMT) - simplywall.st
Is Summit Therapeutics Inc. forming a bottoming baseJuly 2025 Rallies & Real-Time Volume Analysis - newser.com
Is Summit Therapeutics Inc. stock supported by strong cash flowsRisk Management & Safe Entry Zone Identification - newser.com
A Look at Summit Therapeutics (SMMT) Valuation Following Phase III Trial Setback and Legal Investigation - Yahoo Finance
H.C. Wainwright Reaffirms Price Target for Summit Therapeutics (SMMT) After Ivonescimab Milestones - MSN
Alpha Buying: The 3 Stocks That Just Got This $1 Million Vote of Confidence - Benzinga
Summit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025 - Yahoo Finance
Will Summit Therapeutics Inc. stock continue dividend increasesJuly 2025 Catalysts & Verified Momentum Stock Ideas - newser.com
Published on: 2025-09-30 03:00:28 - newser.com
Published on: 2025-09-30 00:09:58 - newser.com
Will Summit Therapeutics Inc. stock gain from lower inflationWeekly Profit Recap & Pattern Based Trade Signal System - newser.com
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug - MSN
What analysts say about Summit Therapeutics Inc stockResistance Zone Identification & Free Stock Education Platform for New Investors - earlytimes.in
Summit Therapeutics Inc Stock Analysis and ForecastAI-Driven Market Analysis & Learn From the Strategies of Institutions - earlytimes.in
Positive Catalyst Watch Boosts SMMT Stock Outlook - GuruFocus
Barclays Maintains Summit Therapeutics(SMMT.US) With Sell Rating, Maintains Target Price $13 - 富途牛牛
Summit Therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
First-Ever PD-1 Therapy Superiority: Summit's Ivonescimab Achieves Breakthrough in Advanced Lung Cancer Trial - Stock Titan
Weekly Analysts’ Ratings Updates for Summit Therapeutics (SMMT) - Defense World
Voya Investment Management LLC Sells 34,041 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics PLC $SMMT Shares Sold by Wealth Management Partners LLC - MarketBeat
Barclays Begins Coverage on Summit Therapeutics (NASDAQ:SMMT) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Summit Therapeutics Inc. (SMMT) And Encourages Shareholders to Connect - ACCESS Newswire
Summit Therapeutics Inc. stock chart pattern explainedWeekly Profit Recap & Accurate Intraday Trade Tips - newser.com
Primer: Summit Therapeutics (SMMT US)Sep 2025 - Smartkarma
Summit Therapeutics (NASDAQ:SMMT) Coverage Initiated at Barclays - MarketBeat
Summit Therapeutics Inc. (SMMT) Faces Volatile 2025 as Ivonescimab Gains Approval in China - MSN
Will Summit Therapeutics Inc. benefit from macro trendsJuly 2025 Fed Impact & High Conviction Investment Ideas - newser.com
Summit Therapeutics (NASDAQ:SMMT) Given Buy Rating at HC Wainwright - MarketBeat
Aug Catalysts: Is Summit Therapeutics Inc benefiting from innovation trendsTrade Entry Summary & Reliable Price Breakout Signals - خودرو بانک
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.33%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):